Lung Cancer
-
FDA Denies Approval for Summit Therapeutics’ Ivonescimab in Lung Cancer
The FDA rejected Summit Therapeutics’ ivonescimab for EGFR-mutated lung cancer, citing a lack of a statistically significant overall survival benefit.
-
How will the next era of precision thoracic oncology change treatment choices for lung‑cancer patients?
How modern molecular targets, blood-based biomarkers, and personalized therapies are reshaping treatment choices for lung-cancer patients.
-
SABR Versus Surgery: New Study Reveals Mortality Gap for Early-Stage Lung Cancer
Large population study finds SABR linked to higher three-year mortality than surgery, but gap narrows significantly for patients 80 and older.
-
Imdelltra Plus Imfinzi Cuts Risk of Death 58% in Small Cell Lung Cancer Trial
New Phase 3 data reveals that combining Imdelltra with Imfinzi slashes death risk by 58% in patients with extensive-stage small cell lung…
-
Large U.S. Study Links Cannabis Use Disorder to Nearly Four Times the Lung Cancer Risk
WASHINGTON, July 15 — A new case-control study, the largest of its kind ever conducted in the United States, has delivered a…
-
NYU Study Finds Lung Tumors Can Trigger Cancer Wasting Through the Vagus Nerve
For the first time, researchers have mapped a direct biological chain from a specific lung tumor mutation to the nervous system, with…
-
Study: Quitting Smoking for Vaping Raises Lung Cancer Risk 56%
SEOUL — A sweeping new study out of South Korea is casting serious doubt on the idea that switching to e-cigarettes is…
-
Study: Ex-Smokers Who Vape Daily Face 56% Higher Lung Cancer Risk
SEOUL — The numbers are brutal. A 56% higher lung cancer risk for former smokers who swap cigarettes for daily vaping. Not…
-
Roche Launches 7-Minute Lung Cancer Injection in India to Replace Hours-Long IV Infusions
For lung cancer patients in India, the treatment chair has been a fixed point — hours of intravenous drip, hospital waits, repeated…
-
Roche Brings 7-Minute Lung Cancer Shot to India at About ₹3.7 Lakh a Dose
MUMBAI — For lung cancer patients in India, a treatment that once meant sitting for an hour or more with an IV…
-
Roche Launches Subcutaneous Lung Cancer Immunotherapy in India
MUMBAI — The needle goes in. Seven minutes later, it’s over. That is the new reality for lung cancer patients in India,…
-
7-Minute Injection To Treat Lung Cancer Comes To India
MUMBAI, June 9, 2026 — infopulsetoday.com — Roche Pharma India has announced the launch of Tecentriq® (atezolizumab) SC in India, the country’s…
-
Columbia and Tübingen Researchers Find Protein NFIL3 Drives CAR T-Cell Exhaustion
Engineered immune cells known as CAR‑T cells have revolutionized treatment for blood cancers, yet their impact on solid tumors such as breast,…
-
FDA Approves Lazertinib With Amivantamab as First-Line Treatment for EGFR Lung Cancer
For patients with a common form of lung cancer, a new treatment option arrived in the United States on August 15, 2024.…
-
FDA Approves Yuhan’s Lazertinib, First Korean-Developed Cancer Drug to Win Approval
South Korea, August 16, 2024 — cyberinktimes.com — Almost four years after South Korean regulators gave it the green light, Lazertinib has…
-
Lazertinib Approved in US for Non-Small Cell Lung Cancer Treatment
In August 2024, the U.S. Food and Drug Administration granted approval for lazertinib, expanding the therapeutic arsenal against non‑small cell lung cancer…
-
FDA Approves Lung Cancer Drug Augtyro for ROS1-Positive Tumors, Trial Shows Responses
The U.S. Food and Drug Administration granted approval on November 15, 2023, for Repotrectinib, marketed as Augtyro, to treat a defined group…
Most read
-
First Human Data on ER-100: What the Sinclair-Linked Eye Gene Therapy Actually Showed
-
AACR Report Details Rapid Progress in Targeted Cancer Therapies and Survival
-
Study Links High Sugar Intake to 28% Higher Breast Cancer Risk in Korean Women
-
How Dynasty Trusts Preserve Wealth for a Century Using GST Exemptions
-
BMS GPRC5D CAR-T Arlo-cel Shows Deep Responses After BCMA Failure
-
How Major Medical Centers Partner With Tech Firms for Next-Gen Proton Therapy
-
FDA Denies Approval for Summit Therapeutics’ Ivonescimab in Lung Cancer
-
How will the next era of precision thoracic oncology change treatment choices for lung‑cancer patients?
-
FDA Approval Moves Astellas’ Padcev Into Curative Bladder Cancer Setting
-
Missed NHS England cancer‑treatment target threatens bladder‑cancer surgery waiting times
-
Navigating 7% Mortgage Rates: Strategies for Buying a Home Now
-
Workers Can Boost Tax Savings by Maximizing New $3,500 Health FSA Limit for 2027
-
Fidelity’s Shift to Managed Accounts and Private Assets: What It Means for 401(k) Savers
-
How Required Minimum Distributions Work and Strategies to Lower Taxes
-
BMS GPRC5D CAR-T Arlo-cel Shows Deep Responses After BCMA Failure
-
Understanding the FDA’s Accelerated Approval of Iberdomide for Multiple Myeloma
-
Rockefeller’s 2141-V11 Trial Shows Complete Remission in Two Metastatic Cancer Patients
-
Ellie Sullivan: Genetic Testing Refused for a Decade, Then Offered After Her Diagnosis
-
Personalized mRNA Cancer Vaccine Succeeds in First Phase 3 Melanoma Trial
-
Indiana University Study Ties Delayed Colorectal Cancer Treatment to Higher Metastasis Risk
-
Study: People Who Drank More Water With Meals Ate More Food, Not Less
-
Why Mornings Are Hardest With ADHD: Late Body Clocks, Poor Sleep and Dopamine
-
Immunotherapy and Genome-Based Vaccines Put the Immune System to Work Against Disease
-
Geneticist John Hardy Proposed Alzheimer’s Amyloid Hypothesis in 1992

















